2026-04-17T06:19:27Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1240342025-12-05T12:25:01Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Jiménez Ubieto, Ana author Grande, Carlos author Caballero, Dolores author Yáñez, Lucrecia author Novelli, Silvana author Hernández, Miguel T. author Manzanares, María author Arranz, Reyes author Ferreiro, José Javier author Bobillo, Sabela author Mercadal, Santiago author Galego, Andrea author López Jiménez, Javier author Moraleda, José María author Vallejo, Carlos author Albo, Carmen author Pérez, Elena author Marrero, Carmen author Magnano, Laura author Palomera, Luis author Jarque, Isidro author Coria, Erika author Rodriguez, Antonia author Martín, Alejandro author López Guillermo, Armando author Salar, Antonio author Lahuerta, Juan José author GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) author 2018-07-27T12:16:59Z 2018-07-27T12:16:59Z 2017-12-01 2018-07-24T11:53:51Z Overall survival (OS) is the gold-standard end point for studies evaluating autologous stem cell transplantation (ASCT) in follicular lymphoma (FL), but assessment may be elusive due to the lengthy disease course. We analyzed the validity of two earlier end points, proposed in the setting of first-line chemo-/immunotherapy, as surrogates for OSprogression-free survival (PFS) status at 24months (PFS24) and complete response at 30months (CR30) post-ASCT. We also have investigated the clinical features of patients with early progression after ASCT. Data were available for 626 chemosensitive FL patients who received ASCT between 1989 and 2007. Median follow-up was 12.2years from ASCT. In the PFS24 analysis, 153 (24%) patients progressed within 24months and 447 were alive and progression-free at 24months post-ASCT (26 who died without disease progressions within 24months were excluded). Early progression was associated with shorter OS (hazard ratio [HR], 6.8; P=0.00001). In the subgroup of patients who received an ASCT in the setting or relapse after being exposed to rituximab, the HR was 11.3 (95% CI, 3.9-30.2; P<0.00001). In the CR30 analysis, 183 of 596 (31%) response-evaluable patients progressed/died with 30months post-ASCT. The absence of CR30 was associated with shorter OS (HR, 7.8; P<0.00001), including in patients with prior rituximab (HR, 8.2). PFS24 and CR30 post-ASCT are associated with poor outcomes and should be primary end points. Further research is needed to identify this population to be offered alternative treatments. Limfomes Cèl·lules mare Lymphomas Stem cells Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma